Core Viewpoint - Southbound funds have increased their holdings in Fosun Pharma (02196.HK) by 499,500 shares on December 11, with a total net increase of 1,437,000 shares over the last five trading days and 1,806,000 shares over the last twenty trading days [1] Company Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is primarily engaged in the research, manufacturing, and sales of pharmaceutical products [1] - The company operates through five segments: - Pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccine business - Medical devices and diagnostics segment involves the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic medical beauty devices - Healthcare services segment operates an integrated online and offline medical service platform - Pharmaceutical distribution and retail segment is involved in the wholesale and retail of pharmaceutical products - Other segments engage in various pharmaceutical-related businesses [1] Shareholding Structure - As of now, southbound funds hold 316 million shares of Fosun Pharma, accounting for 57.28% of the company's total issued ordinary shares [1]

Core Viewpoint - Southbound funds reduced their holdings in Fosun Pharma (02196.HK) by 118,000 shares on November 21, 2025, while showing a net increase in holdings over the past trading days [1][2]. Group 1: Southbound Fund Activity - Over the last five trading days, southbound funds increased their holdings on four occasions, with a total net increase of 1,302,500 shares [1]. - In the last twenty trading days, there were fifteen days of net increases, totaling 9,318,500 shares [1]. - As of now, southbound funds hold 316 million shares of Fosun Pharma, representing 57.28% of the company's total issued ordinary shares [1][2]. Group 2: Shareholding Changes - On November 21, 2025, the total number of shares held was 316 million, with a decrease of 118,000 shares, reflecting a change of -0.04% [2]. - On November 20, 2025, there was an increase of 194,500 shares, showing a change of 0.06% [2]. - The highest increase in the last five trading days occurred on November 19, 2025, with an addition of 885,500 shares, representing a change of 0.28% [2]. Group 3: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five segments [2]. - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines [2]. - The medical devices and diagnostics segment is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2].

Core Viewpoint - Southbound funds increased their holdings in Fosun Pharma (02196.HK) by 316,500 shares on October 22, 2025, despite experiencing net reductions in holdings on several days in the preceding weeks [1][2]. Group 1: Shareholding Changes - Over the last five trading days, there were two days of net reductions in holdings, totaling a net decrease of 296,000 shares [1]. - In the last twenty trading days, there were twelve days of net reductions, resulting in a cumulative net decrease of 16.5155 million shares [1]. - As of now, southbound funds hold 306 million shares of Fosun Pharma, accounting for 55.51% of the company's total issued ordinary shares [1]. Group 2: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five divisions [2]. - The pharmaceutical division focuses on innovative drugs, mature pharmaceutical products, and vaccines [2]. - The medical devices and diagnostics division is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]. - The healthcare services division operates an integrated online and offline medical service platform [2]. - The pharmaceutical distribution and retail division is responsible for the wholesale and retail of pharmaceutical products [2]. - The company's products are mainly used in the treatment of oncology, immunology, and central nervous system disorders [2].

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Fosun Pharma (02196.HK) by 704,000 shares on October 15, 2025, marking a trend of net reductions over recent trading days [1] - Over the past five trading days, southbound funds have reduced their holdings on four occasions, resulting in a total net reduction of 4.34 million shares [1] - In the last twenty trading days, there have been thirteen days of reductions, with a cumulative net decrease of 19.81 million shares [1] Group 2 - As of now, southbound funds hold 307 million shares of Fosun Pharma, which accounts for 55.57% of the company's total issued ordinary shares [1] - The trading data indicates a slight decrease in holdings, with a change of -0.23% on October 15, 2025, and a total holding of 307 million shares [2] - The company operates in five segments, including pharmaceuticals, medical devices, healthcare services, pharmaceutical distribution and retail, and other related businesses, focusing on treatments for oncology, immunology, and central nervous system disorders [2]

Group 1 - The core point of the news is that southbound funds have been reducing their holdings in Fosun Pharma (02196.HK), with a total net reduction of 911.55 million shares over the last five trading days and 2,214.17 million shares over the last twenty trading days [1][2] - As of October 13, 2025, southbound funds hold 310 million shares of Fosun Pharma, accounting for 56.07% of the company's total issued ordinary shares [1][2] - The trading data indicates fluctuations in shareholding, with a decrease of 119.3 million shares on October 13, 2025, representing a change of -0.38% [2] Group 2 - Fosun Pharma operates in five segments: pharmaceutical, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other pharmaceutical-related businesses [2] - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines, while the medical devices segment includes molecular diagnostics and medical beauty devices [2] - The company's products primarily target treatment areas such as oncology, immunology, and central nervous system disorders [2]

Core Viewpoint - Southbound funds reduced their holdings in Fosun Pharma (02196.HK) by 12,500 shares on September 19, 2025, indicating a trend of net selling over the past 20 trading days [1] Group 1: Shareholding Changes - In the last 5 trading days, there were 3 days of net buying by southbound funds, totaling an increase of 744,400 shares [1] - Over the past 20 trading days, southbound funds have reduced their holdings on 15 days, with a total net reduction of 25,690,700 shares [1] - As of now, southbound funds hold 321 million shares of Fosun Pharma, accounting for 58.07% of the company's total issued ordinary shares [1] Group 2: Trading Data - On September 19, 2025, the total number of shares held was 321 million, with a change of -12,500 shares, reflecting a change of -0.00% [2] - On September 18, 2025, the total number of shares held was 321 million, with an increase of 1,714,000 shares, reflecting a change of 0.54% [2] - On September 17, 2025, the total number of shares held was 261 million, with a decrease of 4,086,000 shares, reflecting a change of -1.27% [2] Group 3: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five segments [2] - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines [2] - The medical devices and diagnostics segment is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Fosun Pharma (02196.HK) by 1.714 million shares on September 18, 2025, while experiencing a net reduction of 1.861 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings in Fosun Pharma for 15 days, resulting in a total net reduction of 26.2152 million shares [1] - As of now, southbound funds hold 321 million shares of Fosun Pharma, accounting for 58.07% of the company's total issued ordinary shares [1] Group 2 - The total number of shares held by southbound funds on September 18, 2025, was 321 million, reflecting a change of 1.714 million shares, or an increase of 0.54% [2] - On September 17, 2025, the total shares held decreased by 4.086 million shares, representing a decline of 1.27% [2] - Fosun Pharma operates in five segments, including pharmaceuticals, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other pharmaceutical-related businesses [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Fosun Pharma (02196.HK) by 4.086 million shares on September 17, 2025, marking a decrease of 1.27% in their total holdings [1][2] - Over the past five trading days, southbound funds have reduced their holdings on three occasions, resulting in a cumulative net reduction of 2.5952 million shares [1][2] - In the last twenty trading days, there have been fifteen days of reductions, with a total net decrease of 27.6502 million shares [1][2] Group 2 - As of now, southbound funds hold 319 million shares of Fosun Pharma, which accounts for 57.76% of the company's total issued ordinary shares [1][2] - Fosun Pharma operates in five segments, including pharmaceuticals, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other pharmaceutical-related businesses [2] - The company's products primarily target treatment areas such as oncology, immunology, and central nervous system disorders [2]